• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

MK-4256 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755199

MK-4256 is an effective and selective SSTR3 antagonist (IC50s: 0.66nM and 0.36nM in human and mouse receptor binding assays, respectively). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
MK-4256, Inhibitor
Full Product Name
MK-4256
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
494.52
Solubility
DMSO: 100mg/mL (202.22mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C27H23FN8O
SMILES
CN1N=CC([C@@]2(C3=NOC(C)=N3)N[C@@H](C4=NC=C(C5=CC=C(F)C=C5)N4)CC6=C2NC7=C6C=CC=C7)=C1
CAS Number
1104599-69-0
Target & IC50
uman SSTR3: ic50 0.66nM
mouse SSTR3: ic50 0.36nM
In Vitro
MK-4256 decreases the glucose excursion from 0.003 to 10mg/kg in a dose-dependent manner. MK-4256 decreases glucose excursion in a dose-dependent fashion with maximal efficacy achieves at doses of MK-4256 (0.03mg/kg; p.o.) demonstrates exceptional SSTR3-mediated glucose-lowering efficacy in the mouse oGTT model with minimal hypoglycemia risk. MK-4256 (1mg/kg; p.o.) achieves complete ablation of glucose excursion (109%). The plasma Cmax of MK-4256 is determined from parallel mouse PK studies. MK-4256 achieves Cmax of 7, 88, and 493nM, respectively, at 0.01, 0.1, and 1mg/kg oral dose [1].

Structure of MK-4256, inhibitor

MK-4256 Inhibitor – Cat# MBS5755199

Product References and Citations for MK-4256, inhibitor

He S, et al. The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential treatment,of Type 2 Diabetes. ACS Med Chem Lett. 2012 May 7;3(6):484-9.
He S, et al. The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential treatment,of Type 2 Diabetes. ACS Med Chem Lett. 2012 May 7;3(6):484-9.
He S, et al. Investigation of Cardiovascular Effects of Tetrahydro-beta-carboline sstr3 antagonists. ACS Med Chem Lett. 2014 Apr 21;5(7):748-53.
He S, et al. Investigation of Cardiovascular Effects of Tetrahydro-beta-carboline sstr3 antagonists. ACS Med Chem Lett. 2014 Apr 21;5(7):748-53.

Other Notes

Small volumes of MK-4256, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for MK-4256 purchase

MBS5755199 is an inhibitor targeting MK-4256.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000